Topics

Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma

06:11 EDT 2 May 2019 | Pharmaceutical Business Review

The primary endpoint of the trial is progression-free survival, and the secondary endpoints are overall survival and objective response rate. “Clinical observations suggest cabozantinib promotes an immune-permissive environment,

The post Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma appeared first on Pharmaceutical Business review.

Original Article: Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma

NEXT ARTICLE

More From BioPortfolio on "Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma"

Quick Search